GEN-MKT-18-7897-A
Feb 18, 2026 | Biopharma, Blogs, Pharma | 0 comments
Read time: 3 minutes
For decades, SCIEX has been part of bioanalytical innovation, empowering scientists in pharma and biopharma to push the boundaries of sensitivity, accuracy, and throughput. Across complex workflows and increasingly challenging therapeutic modalities.
Today, we’re spotlighting three peer‑reviewed publications, spanning nearly thirty years, that reflect how the scientific community continues to innovate. From oligonucleotide quantitation to protein bioanalysis, these studies highlight the evolution in the field and the long-term partnerships we value.
Publication: 🔗 https://pubs.acs.org/doi/full/10.1021/ac0618674
The study showcased how thoughtful chromatographic design, structured optimization, and careful attention to matrix effects could deliver reliable quantitation even in challenging biological samples. Many of the best practices introduced here, including instrument stability, ionization efficiency, and systematic validation, still underpin quantitative workflows today.
Abstract
Electrospray ionization (ESI) liquid chromatography−tandem mass spectrometry (LC/MS/MS) assays provide high-throughput and selective methods for quantitation of small molecules. Use of LC/MS/MS assays for macromolecules, like oligonucleotides, is challenging due to lack of sensitivity and low analyte recovery from biomatrixes. Due to this fact, the method of choice for oligonucleotides quantitation remains hybridization-based ligand-binding assays…
Publication: 🔗 https://pubs.acs.org/doi/full/10.1021/ac501837t
This publication introduced an innovative, cost-effective approach for protein depletion using combinations of organic solvents and acids, validated through signature peptide monitoring. The result? Cleaner extracts, improved sensitivity, and greater confidence in LC–MS/MS quantitation of therapeutic proteins.
We have developed an innovative method to remove albumin from plasma/serum samples for the LC-MS/MS quantitation of therapeutic proteins. Different combinations of organic solvents and acids were screened for their ability to remove albumin from plasma and serum samples. Removal efficiency was monitored by two signature peptides (QTALVELVK and LVNEVTEFAK) from albumin …
Publication: 🔗 https://www.tandfonline.com/doi/full/10.1080/…
This 2024 publication captures the cutting edge: hybridization‑based LC–MS/MS approach to measure trace levels of free antisense oligonucleotide payload in complex biological matrices. It demonstrates how advanced workflows, combining sample prep with sensitive mass spectrometry, are enabling scientists to tackle the challenges of next‑generation modalities.
We have developed an innovative method to remove albumin from plasma/serum samples for the LC-MS/MS quantitation of therapeutic proteins. Different combinations of organic solvents and acids were screened for their ability to remove albumin from plasma and serum samples. Removal efficiency was monitored by two signature peptides (QTALVELVK and LVNEVTEFAK) from albumin. Isopropanol with 1.0% trichloroacetic acid was found to be the most effective combination to remove albumin while retaining the protein of interest. Our approach was compared with a commercial albumin depletion kit on both efficiency of albumin removal and recovery of target proteins…
Each decade has brought new questions and new scientific ingenuity to the forefront. And through it all, SCIEX solutions and partnerships have helped researchers stay ahead of the curve.
As therapeutic innovation accelerates, bioanalysis will continue to evolve. Modalities will diversify. Performance expectations will rise. Workflows will become more hybrid, more integrated, and more data‑driven. SCIEX is committed to supporting scientists on that journey with tools designed not just for today’s challenges, but for tomorrow’s discoveries.
Ready to advance your bioanalysis workflows further?
Explore SCIEX Bioanalysis & DMPK Applications pages >
Discover solutions, workflows, and technical insights designed to help you push sensitivity, accelerate method development, and solve complex quantitation challenges.
Join the BioA Collective on LinkedIn >
Connect with a global community of bioanalytical scientists, share expertise, and stay inspired by real‑world innovation.
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Posted by
You must be logged in to post a comment.
Share this post with your network